www.archtherapeutics.com Open in urlscan Pro
3.72.124.16  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Home
 * About
   * Corporate Mission
   * Leadership
   * Advisors
 * Products
   * Ordering Information
   * Intellectual Property
   * AC5 Advanced Wound System
 * Technology
   * Platform
   * Preclinical Data
   * Clinical Data
 * Pipeline
   * Pipeline Opportunity
 * Investors
      
    * Investor Relations
    * IR Overview
   
    * News
    * Press Releases
    * IR Calendar
    * Presentations
    * Interviews
   
    * Stock Data
    * Quote
    * Charts
    * Historical Data
    * Analyst Coverage
   
    * SEC Filings
    * All SEC Filings
    * Annual Reports
    * Quarterly Reports
    * Section 16 Filings
   
    * Corporate Governance
    * Governance Documents

 * Contact


DERMAL SCIENCES UPDATE
ARCH LAUNCHES
AC5® ADVANCED WOUND SYSTEM
WEBSITE

View Site







•••••••


DERMAL SCIENCES UPDATE
ARCH LAUNCHES
AC5® ADVANCED WOUND SYSTEM
WEBSITE

View Site


DERMAL SCIENCES UPDATE
WORLD-RENOWNED WOUND CARE LEADERS, TERRY TREADWELL, MD, FACS AND BROCK LIDEN,
DPM, SHARE INSIGHTS ON SUCCESS WITH AC5 ADVANCED WOUND SYSTEM AT SAWC SPRING
2022

Your browser doesn't support HTML5 video. Here is a link to the video instead.


DERMAL SCIENCES UPDATE
CLINICAL EVALUATION OF
AC5® ADVANCED WOUND SYSTEM
PUBLISHED IN JANUARY 2022
ISSUE OF WOUNDS

View Article


DERMAL SCIENCES UPDATE
EXPERTS IN WOUND CARE SERIES

Watch KOL Interviews


DERMAL SCIENCES UPDATE
AC5® ADVANCED WOUND SYSTEM
PUBLISHED IN OCTOBER 2021
ISSUE OF TODAY'S WOUND CLINIC

View Article


BIOSURGERY UPDATE
NOVEL SELF-ASSEMBLING AGENT, AC5-G™, FOR USE IN SUBMUCOSAL LIFTING IN ENDOSCOPIC
RESECTION AND MANAGEMENT OF GASTROINTESTINAL BLEEDING

Your browser doesn't support HTML5 video. Here is a link to the video instead.

View Video


2022 ANNUAL MEETING OF STOCKHOLDERS

Recent Webcast


ABOUT ARCH THERAPEUTICS


Arch Therapeutics, Inc. is a biotechnology company developing a novel approach
to stop bleeding (hemostasis), control leaking (sealant) and manage wounds
during surgery, trauma and interventional care. Arch is developing products
based on an innovative self-assembling barrier technology platform with the goal
of making care faster and safer for patients. Arch has received regulatory
authorization to market AC5 Advanced Wound System and AC5 Topical Hemostat as
medical devices in the United States and Europe, respectively. Arch's
development stage product candidates include AC5-G, AC5-V and AC5 Surgical
Hemostat, among others.1,2


1. AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices
limited by law to investigational use.
2. AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered
trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.


RECENT NEWS VIEW ALL NEWS

09/23/22:
Arch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under
New Reimbursement Support
09/20/22:
Arch Therapeutics Accepted to Present AC5® Advanced Wound System During
Innovation Spotlight at 2022
10/07/2022 03:34 PM EDT
ARTH
OTCQB
$0.0455
Price
Volume
502.81k
Market Cap
$11.37m
Change
0.0055


ABOUT

Learn more about Arch Therapeutics and
 its leadership team, poised to meet the
challenges of applying innovative biotechnology to develop advanced
interventional wound care products.

Learn More


TECHNOLOGY

The wound care market seeks products that work better, faster, & more reliably.
See how Arch Therapeutics’ platform can address those needs.

Learn More


PIPELINE

Find out more about Arch Therapeutics’ product candidates.

Learn More


PRESENTATIONS

Find Arch Therapeutics’ recent presentations and more.

Learn More


LEARN MORE

 * 
 * 
 * Email Alerts
 * Tearsheet


CONTACT US

235 Walnut Street, Suite 6
Framingham, MA 01702
Phone: +1-800-937-9030


INVESTOR RELATIONS

ARTH Investor Relations
Phone: +1-855-340-2784
Email: investors@archtherapeutics.com

© 2022 Arch Therapeutics, Inc. All rights reserved. Privacy Policy Disclaimer
Sitemap